| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.21 | 0.0006 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.2 | 0.003 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.003 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.004 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.14 | 0.004 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.007 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.007 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.16 | 0.009 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.097 | 0.009 |